These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37461963)

  • 1. P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Lopes M; Shintaku D; de Oliveira AC; Beraldo R; Godoi G; Castelhano N; Vulcano D; Pereira J; de Oliveira EC; Herrerias G; Saad-Hossne R; Baima J; Barbosa W; Silva G; Sassaki L
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11-S12. PubMed ID: 37461963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
    Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
    [No Abstract]   [Full Text] [Related]  

  • 3. P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Shintaku D; Lopes M; de Oliveira AC; Beraldo R; Godoi G; Castelhano N; Pereira J; Vulcano D; de Oliveira EC; Herrerias G; Saad-Hossne R; Baima J; Barbosa W; Silva G; Sassaki L
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S12-S13. PubMed ID: 37461967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Sourianarayanane A; Garg G; Smith TH; Butt MI; McCullough AJ; Shen B
    J Crohns Colitis; 2013 Sep; 7(8):e279-85. PubMed ID: 23158500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
    Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
    Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
    Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
    Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.
    Losurdo G; La Fortezza RF; Iannone A; Contaldo A; Barone M; Ierardi E; Di Leo A; Principi M
    World J Gastroenterol; 2020 Dec; 26(47):7528-7537. PubMed ID: 33384552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Zamani M; Alizadeh-Tabari S; Singh S; Loomba R
    Aliment Pharmacol Ther; 2022 Apr; 55(8):894-907. PubMed ID: 35274325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
    Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
    World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of body muscle mass as an indicator of activity in inflammatory bowel disease patients.
    Zalizko P; Roshofa TH; Meija L; Bodnieks E; Pukitis A
    Clin Nutr ESPEN; 2020 Dec; 40():193-200. PubMed ID: 33183536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego Llera B; Refaie E; Callau P; Mendi C; Baptista PM; Hernández Ainsa M; Arroyo-Villarino MT; López de la Cruz J; Martínez-García J; Alfambra E; Simón Marco MÁ; Ampuero J; Gomollón F
    Eur J Intern Med; 2024 Feb; 120():99-106. PubMed ID: 37872034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy.
    Likhitsup A; Dundulis J; Ansari S; Patibandla S; Hutton C; Kennedy K; Helzberg JH; Chhabra R
    Ann Gastroenterol; 2019; 32(5):463-468. PubMed ID: 31474792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
    PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASE.
    Lacombe LAC; Matiollo C; Rosa JSD; Felisberto M; Dalmarco EM; Schiavon LL
    Arq Gastroenterol; 2022; 59(2):238-243. PubMed ID: 35830035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of non-alcoholic fatty liver disease in patients with Crohn's disease but not ulcerative colitis.
    Li D; Lu C; Yu C
    Int J Clin Exp Pathol; 2017; 10(10):10633-10639. PubMed ID: 31966406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.